SavedAdd your journal

Journals / Zeugma Biological Science / 2022 / Cilt: 3 - Sayı: 3

Hormone`s role in development and energy regulation (Review Article)

Ishtar IMAD
Suhail BAYATİ
Pages
1–9
Publication Date
2022-08-24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The sensitivity of lipid biomarkers such as LDL-C, HDL-C, TC, TG, Apo-A, and Apo-B after rehabilitation of the thyroid profile to achieve a euthyroid state was determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Asprosin, in addition to performing a glucogenic function, is a centrally acting orexigenic hormone that represents a potential therapeutic target for the treatment of obesity and diabetes.
📊
Key Findings & Data:Perturbations in the action of T3 and T4 affect normal metabolic pathways.
💡
Conclusion & Impact:The sensitivity of lipid biomarkers such as LDL-C, HDL-C, TC, TG, Apo-A, and Apo-B after rehabilitation of the thyroid profile to achieve a euthyroid state was determined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Asprosin · HDL-C · Apo-A

Abstract

Asprosin, in addition to performing a glucogenic function, is a centrally acting orexigenic hormone that represents a potential therapeutic target for the treatment of obesity and diabetes. Perturbations in the action of T3 and T4 affect normal metabolic pathways. The sensitivity of lipid biomarkers such as LDL-C, HDL-C, TC, TG, Apo-A, and Apo-B after rehabilitation of the thyroid profile to achieve a euthyroid state was determined.

🔖

Cite This Article

IMAD, I., BAYATİ, S. (2022). Hormone`s role in development and energy regulation (Review Article). Zeugma Biological Science, Cilt: 3 - Sayı: 3, 1–9. https://ajindex.com/articles/823687

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Mogulkoc, Rasim & Dasdelen, Dervis & Baltaci, Saltuk & Baltaci, Abdulkerim Kasim & Sivrikaya, Abdullah. (2020). The effect of thyroid dysfunction and treatment on drop-in, asprosin, and preptin levels in rats. Hormone Molecular Biology and Clinical Investigation. -1. 10.1515/hmbci-2020-0058.
  2. Naiemian, S., Naeemipour, M., Zarei, M. et al. (2020). Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr 12, 65https://doi.org/10.1186/s13098-020-00564-w.
  3. Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M, Jia P, Zhao Z, Farias M, Wu Q, Milewicz DM, Sutton VR, Moore DD, Butte NF, Krashes MJ, Xu Y, Chopra AR. (2017 ). Asprosin is a centrally acting orexigenic hormone. Nat Med. Dec;23(12):1444-1453. doi: 10.1038/nm.4432. Epub 2017 Nov 6. PMID: 29106398; PMCID: PMC5720914. Naiemian, Shakiba and Naeemipour, Mohsen, el al. (2020). The serum concentration of asprosin in new-onset type 2 diabetes. Diabetology & Metabolic Syndrome. 65: 12: 1. Asprosin, a newly identified adipokine, is pathologically increased in individuals with insulin resistance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status.1758-5996.https://doi.org/10.1186/s13098-020-00564-w.bvgbbfB.
  4. K. Ugur, F. Erman, S. Turkoglu, Y. Aydin, A. Aksoy, A. Lale, Z.K. Karagöz, İ. Ugur, R.F. Akkoc, M. Yalniz. (2022). Asprosin, visfatin, and subfatin as new biomarkers of obesity and metabolic syndrome. Eur Rev Med Pharmacol Science. Vol. 26 - N. 6. 2124-2133.DOI: 10.26355/eurrev_202203_28360. Al-Daghri, Nasser M., Reem M.I. Alokeel, Abir Alamro. (2022). Serum asprosin levels are associated with obesity and insulin resistance in Arab adults. Journal of King Saud University – Science. Volume 34, Issue 1. Atici E, Menevse E, Baltaci AK, Mogulkoc R. (2018 ). Both experimental hypothyroidism and hyperthyroidism increase cardiac irisin levels in rats. Bratislavske Lekarske Listy.119(1):32-35. DOI: 10.4149/bll_2018_007. PMID: 29405728. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. (2016). Asprosin, is a fasting-induced glucogenic protein hormone. Cell. 165:566–79. doi: 10.1016/j.cell.2016.02.063. Lee T, Yun S, Jeong JH, Jung TW. (2019). Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation